Thermalin, Inc. has entered a worldwide collaboration with Sanofi to discover and develop novel, engineered insulin analogues. The collaboration leverages Thermalin’s science, which alters the insulin molecule to achieve greater therapeutic performance. The collaboration could generate as much as $788 million in equity investments, milestone payments, and R&D services for Thermalin, of which $9 million was paid upfront. Sanofi will assume the clinical development costs of these insulin pr...